The WAPO webinar series presents a series of educational sessions available from the WAPO website. The first in the 2023 series is from Ignas Meškauskas, Health, and Life Coach and founder of a practical wellness practice
The Spanish Association of Endocrinology and Nutrition held its 63rd annual congress this October 26 to 29. The Spanish association SEEN (Sociedad Española de Endocrinología y Nutricíon) presented an excellent agenda, including the latest endocrine
COR2ED is an independent medical education company based in Europe. They have partnered with a scientific committee comprising endocrinologists, nurses, and patient advocacy groups (WAPO and INCA) to develop two surveys to explore the injection
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.
Rare disease patient organizations including those representing pituitary patients demanded governmental and health authorities for an immediate resolution on the availability of medications.
If you have been recently diagnosed with acromegaly this flyer provides an excellent resource to better understand the disease. This is a collaborative effort between Pfizer’s global offices in Belgium, several patient advocacy groups, and
Help us increase the medical field’s knowledge of CDI by participating in this short five-minute anonymous survey. An international team of researchers will collect the patient data to help physicians and patients understand how to manage DI
Chile’s Acromegaly support group CORAPEHI focuses on access to Pegvisomant in their struggle to improve access to medication for acromegaly patients in that country. Since 2010 Acromegaly Chile and CORAPEHI (Corporation to Help Patients with
From the editor’s desk – For organizations in the pituitary space, we believe it is critically important to reach out to a broader audience to make the case that these conditions, although classified as rare,
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
Acromegaly patients and healthcare providers worldwide can participate in this survey and provide updated information that may help improve quality of life during the COVID-19 pandemic. Much of this initiative’s success will depend on your